This study is completed in the United States. It is testing Safety and Efficacy of CTP-692 for schizophrenia.
SchizophreniaDrugFrom 18 Years to 55 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether CTP-692 may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive CTP-692, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: November 26, 2019
Recruitment status
Completed
Enrollment listed in the registry
326
Sponsor
Concert Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT04158687
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adult Patients With Schizophrenia
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT04158687. We help you review the study, but cannot decide medical eligibility.
Recruitment & locations
Completed
Little Rock · Rogers · Cerritos
21 more locations
Culver City
Garden Grove
Lemon Grove
Oakland
Torrance
Lauderhill
North Miami
Atlanta
Chicago
Lincolnwood
Gaithersburg
St Louis
Las Vegas
Berlin
Marlton
Cedarhurst
Jamaica
Charleston
Austin
DeSoto
Richardson
FAQ
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of CTP-692 for people with schizophrenia.
Who is behind this study?
The study sponsor is Concert Pharmaceuticals.
Does this study involve medication?
Yes. The study involves medication, including CTP-692 and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as completed.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
